9 7 8 1 6
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
CDK4/6 抑制及在乳腺癌治疗中的最新进展
Authors Wu Y, Zhang Y, Pi H, Sheng Y
Received 20 February 2020
Accepted for publication 16 April 2020
Published 15 May 2020 Volume 2020:12 Pages 3477—3487
DOI https://doi.org/10.2147/CMAR.S250632
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
摘要：选择性 CDK4/6 抑制剂的临床应用显著改善了 HR+/HER2-晚期或转移性乳腺癌患者的预后。CDK4/6 抑制剂联合内分泌治疗方案患者的无进展生存期几乎翻倍。目前，FDA 和 EMA 批准上市的 CDK4/6 抑制剂主要有三个：哌柏西利，Ribociclib 和 Abemaciclib。本篇综述介绍了 CDK4/6 抑制剂的作用机制，总结了 CDK4/6 抑制剂的主要临床研究和正在进行的一些临床研究，以及已经发表的总生存数据；并就潜在的生物标志物及耐药基因进行了探讨。
关键词：CDK4/6 抑制剂；乳腺癌；作用机制；临床疗效；耐药
